Page 19 - GTM-3-4

Global Translational Medicine Parkinson’s: From cause to cure

Genes (Basel). 2022;13(3):471. Parkinson’s disease therapeutics. Expert Opin Drug Discov.
2020;15(1):53-62.
doi: 10.3390/GENES13030471
doi: 10.1080/17460441.2020.1691165
31. Kamath T, Abdulraouf A, Burris SJ, et al. Single-cell
genomic profiling of human dopamine neurons identifies 41. Fabbri M, Ferreira JJ, Rascol O. COMT Inhibitors in
a population that selectively degenerates in Parkinson’s the management of Parkinson’s disease. CNS Drugs.
disease. Nat Neurosci. 2022;25(5):588-595. 2022;36(3):261-282.
doi: 10.1038/S41593-022-01061-1 doi: 10.1007/S40263-021-00888-9
32. Demailly A, Moreau C, Devos D. Effectiveness of continuous 42. Woitalla D, Buhmann C, Hilker-Roggendorf R, et al. Role of
dopaminergic therapies in Parkinson’s disease: A review dopamine agonists in Parkinson’s disease therapy. J Neural
of L-DOPA pharmacokinetics/pharmacodynamics. Transm (Vienna). 2023;130(6):863-873.
J Parkinsons Dis. 2024;14:925-939. doi: 10.1007/S00702-023-02647-0
doi: 10.3233/jpd-230372 43. Jing XZ, Yang HJ, Taximaimaiti R, Wang XP. Advances in
33. Farzanehfar P, Woodrow H, Horne M. Assessment of wearing the therapeutic use of non-ergot dopamine agonists in the
off in Parkinson’s disease using objective measurement. treatment of motor and non-motor symptoms of Parkinson’s
J Neurol. 2021;268(3):914-922. disease. Curr Neuropharmacol. 2023;21(5):1224-1240.
doi: 10.1007/s00415-020-10222-w doi: 10.2174/1570159X20666220915091022
34. Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. 44. Gray R, Ives N, Rick C, et al. Long-term effectiveness of
Recent advances in drug therapy for Parkinson’s disease. dopamine agonists and monoamine oxidase B inhibitors
Intern Med. 2023;62(1):33-42. compared with levodopa as initial treatment for Parkinson’s
disease (PD MED): A large, open-label, pragmatic
doi: 10.2169/internalmedicine.8940-21 randomised trial. Lancet. 2014;384(9949):1196-1205.

35. LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of doi: 10.1016/S0140-6736(14)60683-8
CVT-301 (levodopa inhalation powder) on motor function
during off periods in patients with Parkinson’s disease: 45. Rose EP, Osterberg VR, Gorbunova V, Unni VK. Alpha-
A randomised, double-blind, placebo-controlled phase 3 synuclein modulates the repair of genomic DNA double-
trial. Lancet Neurol. 2019;18(2):145-154. strand breaks in a DNA-PK -regulated manner. Neurobiol
cs
Dis. 2024;201:106675
doi: 10.1016/S1474-4422(18)30405-8
doi: 10.1016/j.nbd.2024.106675
36. Zou D, Liu R, Lv Y, Guo J, Zhang C, Xie Y. Latest advances
in dual inhibitors of acetylcholinesterase and monoamine 46. Price DL, Khan A, Angers R, et al. In vivo effects of the
oxidase B against Alzheimer’s disease. J Enzyme Inhib Med alpha-synuclein misfolding inhibitor minzasolmin supports
Chem. 2023;38(1):2270781. clinical development in Parkinson’s disease. NPJ Parkinsons
Dis. 2023;9(1):114.
doi: 10.1080/14756366.2023.2270781
doi: 10.1038/S41531-023-00552-7
37. Lv Y, Zheng Z, Liu R, Guo J, Zhang C, Xie Y. Monoamine
oxidase B inhibitors based on natural privileged scaffolds: 47. Hariz M, Blomstedt P. Deep brain stimulation for Parkinson’s
A review of systematically structural modification. Int J Biol disease. J Intern Med. 2022;292(5):764-778.
Macromol. 2023;251:126158. doi: 10.1111/JOIM.13541
doi: 10.1016/J.IJBIOMAC.2023.126158 48. Hacker ML, Turchan M, Heusinkveld LE, et al. Deep brain

38. Tan YY, Jenner P, Di Chen S. Monoamine oxidase-B stimulation in early-stage Parkinson disease: Five-year
inhibitors for the treatment of Parkinson’s disease: Past, outcomes. Neurology. 2020;95(4):E393-E401.
present, and future. J Parkinsons Dis. 2022;12(2):477-493. doi: 10.1212/WNL.0000000000009946
doi: 10.3233/JPD-212976 49. Kremer NI, van Laar T, Lange SF, et al. STN-DBS electrode
39. Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P. placement accuracy and motor improvement in Parkinson’s
Redefining the strategy for the use of COMT inhibitors disease: Systematic review and individual patient meta-
in Parkinson’s disease: The role of opicapone. Expert Rev analysis. J Neurol Neurosurg Psychiatry. 2023;94(3):236-244.
Neurother. 2021;21(9):1019-1033. doi: 10.1136/JNNP-2022-329192
doi: 10.1080/14737175.2021.1968298 50. Krishna V, Fishman PS, Eisenberg HM, et al. Trial of globus
pallidus focused ultrasound ablation in Parkinson’s disease.
40. Moschovou K, Melagraki G, Mavromoustakos T,
Zacharia LC, Afantitis A. Cheminformatics and virtual N Engl J Med. 2023;388(8):683-693.
screening studies of COMT inhibitors as potential doi: 10.1056/NEJMOA2202721

Volume 3 Issue 4 (2024) 11 doi: 10.36922/gtm.5082